When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit the ...

On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover ...

GSK said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product lineup. Walmsley will step down at the end of ...

After charting a similar move in Kenya last year, GSK is pulling the plug on its Nigerian operations. Late last week, GSK said it plans to cease commercialization of its prescription medicines and ...

The last time I wrote about GSK plc (GSK) for Seeking Alpha, it was late September, and I was covering the news that its CEO since 2017, Emma Walmsley, was stepping away from the role to be replaced ...